PDT Partners LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 16,300 shares of the company's stock, valued at approximately $2,559,000.
A number of other hedge funds also recently bought and sold shares of the company. Vaughan Nelson Investment Management L.P. bought a new position in TransMedics Group during the 2nd quarter worth approximately $39,862,000. Driehaus Capital Management LLC increased its stake in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company's stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after purchasing an additional 146,115 shares during the last quarter. Hood River Capital Management LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter worth approximately $18,854,000. Finally, Canada Pension Plan Investment Board bought a new position in TransMedics Group during the 2nd quarter valued at approximately $16,086,000. Institutional investors own 99.67% of the company's stock.
A number of research firms have recently commented on TMDX. Piper Sandler cut their target price on TransMedics Group from $180.00 to $110.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a "hold" rating and issued a $109.00 target price on shares of TransMedics Group in a research note on Friday, November 22nd. Baird R W raised shares of TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Oppenheimer lowered their price objective on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. decreased their price target on TransMedics Group from $173.00 to $116.00 and set an "overweight" rating for the company in a research note on Tuesday, October 29th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, TransMedics Group has an average rating of "Moderate Buy" and a consensus target price of $131.80.
Check Out Our Latest Stock Report on TMDX
In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 12.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares of the company's stock, valued at $8,180,642.53. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,958 shares of company stock valued at $3,470,328 over the last three months. Corporate insiders own 7.00% of the company's stock.
Shares of NASDAQ:TMDX traded down $0.40 during trading on Friday, hitting $86.71. The company's stock had a trading volume of 1,027,865 shares, compared to its average volume of 1,604,884. The company has a 50-day moving average of $111.69 and a 200-day moving average of $136.16. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of 92.25 and a beta of 2.08. TransMedics Group, Inc. has a 12 month low of $68.84 and a 12 month high of $177.37.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts' expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm's quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.12) earnings per share. On average, sell-side analysts expect that TransMedics Group, Inc. will post 1.01 earnings per share for the current year.
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.